Welcome to the Inaugural Therapeutic Investigator Day!

October 23, 2023  |  Boston, MA  |  Boston Park Plaza

By invitation only

 

On the heels of the first-ever traditional approval of a disease-modifying therapy for Alzheimer’s, lecanemab, and the anticipated approval of donanemab early next year, it’s apparent that we have entered a new era of Alzheimer’s research. Data on multiple anti-amyloid drugs have validated that this pathway is only modestly effective, bolstering the industry-wide shift towards exploring more novel pathways centered around the biology of aging, and ensuring that this approach continues driving drug development and the next generation of therapies.

 

The Alzheimer’s Drug Discovery Foundation (ADDF) and our funded investigators have played a fundamental role in this shift, as the biology of aging is one of our cornerstone beliefs. We have long touted that combination therapy and precision medicine—which are needed to address the many underlying pathologies of Alzheimer’s—will be necessary to delay and halt disease progression, and eventually stop Alzheimer’s in its tracks. With the evolution of the current robust drug pipeline where over 75% of drugs in the pipeline are exploring novel pathways, the field has also arrived at this consensus.

 

The inaugural Therapeutic Investigator Day presents an exciting opportunity for ADDF-funded scientists to share promising updates from their research based on the biology of aging and engage in thought-provoking conversations on drug and biomarker development and prevention strategies with key thought leaders. The event will also hold forward-looking panels around the future of combination therapy and biomarkers featuring ADDF leadership, renowned scientists, and representatives from pharma and industry.

 

We hope Therapeutic Investigator Day facilitates networking and collaboration among our groundbreaking researchers, as we forge the path towards the next generation of Alzheimer’s drugs.

 

We look forward to delving into our scientists’ innovative research and uncovering new insights.

 

Best wishes,

 

Howard Fillit, MD
Co-Founder and Chief Science Officer
Alzheimer’s Drug Discovery Foundation
Mark Roithmayr
Chief Executive Officer
Alzheimer’s Drug Discovery Foundation

ADDF's Research Portfolio

The ADDF seeks out and funds a diverse research portfolio of drug targets and biomarkers that reflect the many biological pathways and systems involved in neurodegenerative dementias, including inflammation, vascular dysfunction, misfolded proteins, and other mechanisms affected by the biology of aging that may contribute to this complex disease. Our portfolio covers diverse biomarker modalities from neuroimaging to blood tests to digital apps, and therapeutic approaches including gene therapies, biologics, small molecules, and non-pharmacologic devices. Learn more about our open funding opportunities here.

To learn more about the robust and diverse Alzheimer’s research pipeline, where over 75% of drugs target novel pathways beyond amyloid and tau, read the ADDF’s latest Clinical Trials Report.

MEETING HIGHLIGHTS

21 Speakers and Moderators 

Panel Discussions

Q&A

Access to meeting by invitation only 

PROGRAM

All sessions will be held in the Boston Park Plaza’s Square Room on October 23, 2023. Times below are ET.

Session/Lecture

9:00 — 9:30am
Opening Remarks
9:30 — 10:00
KEYNOTE: Treatment of Alzheimer's Disease: Amyloid and Beyond
10:00 — 10:15
The ADDF Clinical Trials Portfolio Roadmap
10:15 — 10:35
Coffee Break
10:35 — 12:30
MORNING SESSION
10:35 — 10:55
Translating the Biology of Aging into New Therapeutics for Alzheimer’s Disease: Senolytics
10:55 — 11:15
Pioneering Fibrin-Targeting Therapies to Treat Neurodegenerative Diseases
11:15 — 11:35
P75 Receptor Modulation for AD: Phase 2a Safety/POM/Exploratory Endpoint Trial
11:35am — 12:25pm
Combination Therapy Panel: Challenges for Combination Therapy Clinical Trials in Alzheimer’s Disease
12:25 — 2:00
Networking Luncheon
2:00 — 2:20
Setting Up and Executing a Study to Evaluate TW001 in Alzheimer’s Patients: Lessons Learned
2:20 — 2:40
Towards a Combined Dopaminergic Therapy in AD
2:40 — 3:00
Targeting Microglia and Neuroinflammation with NTRX-07, an Orally Available CB2 Agonist
3:00 — 3:15
Coffee Break
3:15 — 5:05
AFTERNOON SESSION
3:15 — 4:05
Biomarkers Panel: Future of Biomarkers in Clinical Trials and Clinical Care
4:05 — 4:25
Blood Based Biomarkers Measured by Mass Spec for Use in Clinical Diagnostics and Clinical Trials
4:25 — 4:45
Beyond ATN: ASyn SAA Enhances AD/LBD Diagnosis and Enables Personalized Medicine for Dementias
4:45 — 5:05
APN-1607: A Promising PET Tracer for Tauopathies of all Isoform Types
5:05 — 5:35
Closing Remarks
5:35 — 7:05
Networking Reception

Chair/Speaker

9:00 — 9:30am
Howard Fillit, MD - Alzheimer’s Drug Discovery Foundation
Mark Roithmayr - Alzheimer's Drug Discovery Foundation
9:30 — 10:00
Philip Scheltens, MD, PhD - EQT Life Sciences
10:00 — 10:15
Laura Nisenbaum, PhD - Alzheimer's Drug Discovery Foundation
10:15 — 10:35
Coffee Break
10:35 — 12:30
CHAIR: Aaron Burstein, PharmD - Alzheimer's Drug Discovery Foundation
10:35 — 10:55
Miranda Orr, PhD - Wake Forest University
10:55 — 11:15
Jeffrey Stavenhagen, PhD - Therini Bio
11:15 — 11:35
Frank Longo, MD, PhD - Stanford University/PharmatrophiX
11:35am — 12:25pm
MODERATOR:
Michael Gold, MD
- Neumora
PANELISTS:
Paul Aisen, MD
- USC
Miia Kivipelto, MD - Karolinska Institute
Marwan Sabbagh, MD, FAAN - Barrow Neurological Institute
Philip Scheltens, MD, PhD - EQT Life Sciences
Howard Fillit, MD - Alzheimer's Drug Discovery Foundation
12:25 — 2:00
Networking Luncheon
2:00 — 2:20
Ronald van der Geest, PhD - Treeway
2:20 — 2:40
Giacomo Koch, MD, PhD - Santa Lucia Foundation
2:40 — 3:00
Tony Giordano, PhD - NeuroTherapia
3:00 — 3:15
Coffee Break
3:15 — 5:05
CHAIR: Meriel Owen, PhD - Alzheimer's Drug Discovery Foundation
3:15 — 4:05
MODERATOR:
Niranjan Bose, PhD - Gates Ventures
PANELISTS:
Nicholas Ashton, PhD - University of Gothenburg
Rhoda Au, PhD - Boston University
Randall Bateman, MD - Washington University School of Medicine
Dawn Matthews, MSEE, MBA - ADMdx
Howard Fillit, MD - Alzheimer's Drug Discovery Foundation
4:05 — 4:25
Tim West, PhD - C2N
4:25 — 4:45
Russell Lebovitz, PhD - Amprion
4:45 — 5:05
Bradford Navia, MD, PhD - Aprinoia
5:05 — 5:35
Mark Roithmayr - Alzheimer's Drug Discovery Foundation
Howard Fillit, MD - Alzheimer’s Drug Discovery Foundation
5:35 — 7:05
Networking Reception

PRESENTERS, CHAIRS, MODERATORS AND ORGANIZERS

Paul Aisen
USC

Nicholas Ashton
University of Gothenburg

Rhoda Au
Boston University

Randall Bateman
Washington University

Niranjan Bose
Gates Ventures

Aaron Burstein
ADDF

Howard Fillit, MD
ADDF

Tony Giordano
Neurotherapia

Michael Gold
Neumora

Miia Kivipelto
Karolinska Institutet

Giacomo Koch
Santa Lucia Foundation

Russell Lebovitz
Amprion Inc.

Frank Longo
Stanford Univ./PharmatropiX

Dawn Matthews
ADMdx

Bradford Navia
Aprinoia

Laura Nisenbaum
ADDF

Miranda Orr
Wake Forest University

Meriel Owen
ADDF

Mark Roithmayr
ADDF

Marwan Sabbagh
Barrow Neurological Institute

Philip Scheltens
EQT Life Sciences

Jeffrey Stavenhagen
Therini Bio

Ronald van der Geest
Treeway

Tim West
C2N

ORGANIZING COMMITTEE

Howard Fillit
Alzheimer’s Drug Discovery Foundation

Laura Nisenbaum
Alzheimer’s Drug Discovery Foundation

Aaron Burstein
Alzheimer’s Drug Discovery Foundation

Meriel Owen
Alzheimer’s Drug Discovery Foundation

CONTACT

For any questions, please contact ADDF Meetings at meetings@alzdiscovery.org.

Founded in 1998, the ADDF is the only nonprofit dedicated solely to developing drugs and diagnostics for the treatment and prevention of Alzheimer’s disease and related dementias. Our venture philanthropy investment model combines deep disease-focused expertise with funding for high-risk/high-reward translational programs from academia and biotech companies worldwide.